Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset
Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine, announced a new research study sponsored by Tempus and being run in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, nonprofit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL), marking Tempus’ first study collaboration with a non-profit foundation.
Health Technology Insights: enGene Reports 62% Complete Response for Detalimogene
This multi-year study will enroll FL patients to generate a comprehensive, multi-omic dataset using advanced technologies and techniques, including next generation sequencing, proteomics, and methylation analysis, to facilitate novel research related to precision medicine and biomarker discovery in FL. This study will also contribute critical insights to inform the development and validation of comprehensive whole genome sequencing approaches.
Health Technology Insights: ModelOp Certified by CHAI for Trusted AI in Healthcare
FL is the second most common type of non-Hodgkin lymphoma, accounting for approximately 10-20% of all cases in the U.S1. Despite advances in treatment, about 20% of patients with FL have progressive disease within two years of initial chemoimmunotherapy and a five-year overall survival of 50%. This study builds on Tempus and IFLI’s existing collaboration to create a consolidated, real-world FL data library. By integrating real-world clinical data with advanced molecular profiling, Tempus and IFLI aim to help accelerate the discovery of new insights, support the development of innovative therapies, and enhance outcomes for FL patients worldwide.
“This collaboration with IFLI signifies our shared commitment to generating rich, multimodal datasets that can help transform research for this specific patient population,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “This comprehensive approach will provide researchers with a uniquely deep and actionable understanding of follicular lymphoma, paving the way for new discoveries and personalized treatment strategies.”
“At IFLI, we are dedicated to uniting partners in a shared mission to accelerate breakthroughs in follicular lymphoma care and research, and we are grateful for the collaboration from our network that brought this vision to life. Tempus was selected for its unmatched capabilities in molecular profiling and data science, and we’re confident they are uniquely positioned to deliver on our shared vision,” stated David McCullagh, Managing Director of IFLI. “Together, we aim to create a transformative dataset that integrates real-world clinical insights with advanced testing and analytics to uncover the biological drivers of FL and enable more personalized therapies that improve patient outcomes globally.”
Health Technology Insights: PREFcards Secures U.S. Patent for Innovative Surgical Preference Card Optimization
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
